Today’s current crisis has changed the mindset of many industry strategic partners, investors and overall stakeholders. From pivoting investment priorities, to identifying new areas of innovation, the investor landscape is constantly shifting. For small to medium sized biotechs, it can be hard to keep up with promised milestones while also planning and anticipating the future of their companies. How could companies be preparing for not only the short-term but for years to come? What should be prioritized in the coming months? Who is still investing? How can they find the right partners for them as they move forward?